Pricing & ROI
Mass Tort Lead Generation Cost: What Firms Actually Pay (CPL vs CPSR)
Mass tort lead generation cost is not a single number — a $60 raw lead and a $9,000 signed retainer can come from the same campaign. What a plaintiff firm actually pays to acquire a signed case depends on three distinct metrics: cost per lead (CPL), cost per qualified claimant (CPQC), and cost per signed retainer (CPSR). Treating those as three different numbers, not interchangeable synonyms, is the first step to evaluating whether a vendor relationship is actually working.
- CPL media efficiency
- CPQC screening yield
- CPSR case economics
What mass tort lead generation cost actually includes
Mass tort lead generation cost is made up of media spend, agency margin, intake and screening fees, and technology or compliance overhead. A firm that only looks at a vendor’s quoted CPL is usually seeing one component of a much larger number.
Media spend vs. agency margin
Media spend is the money that actually reaches Google, Meta, and other ad platforms to generate impressions and clicks. Agency margin is layered on top to cover creative production, campaign management, and vendor profit. A firm buying leads at $150 CPL might be looking at $100 in media and $50 in margin, or the reverse, depending on how competitive the ad auction is for that tort. Vendors that disclose the split let firms judge whether margin is reasonable relative to the work being done.
Intake and screening fees
Many vendors charge separately for the labor of calling raw leads, verifying eligibility criteria, and scheduling a case-review call with the firm. These fees are sometimes billed per call attempt and sometimes rolled into a per-qualified-claimant rate. Firms comparing two vendors on CPL alone can miss that one bundles intake and the other invoices it separately — which makes a lower headline CPL misleading.
Technology and compliance costs
CRM integration, call recording, TCPA-compliant consent capture, and duplicate-lead detection all carry real infrastructure cost. Vendors running compliant operations at scale build this into pricing rather than treating it as an afterthought. A materially cheaper CPL from an unfamiliar vendor is worth scrutinizing for what compliance infrastructure, if any, that price is actually funding.
CPL vs. CPQC vs. CPSR — which metric actually matters
CPSR is the metric that matters most for evaluating true mass tort lead generation cost, because it reflects the price of an actual signed retainer rather than an inquiry that may never convert. CPL and CPQC remain useful as earlier-stage checkpoints inside the same funnel.
| Metric | What it measures | What it misses | Best use |
|---|---|---|---|
| CPL | The cost to generate one raw inquiry that clears a basic ad-to-form or call-in conversion. | Whether that inquiry ever becomes a real claimant — or answers the phone at all. | Comparing media efficiency across channels before intake enters the picture. |
| CPQC | The cost to produce one claimant who has passed a defined screening script (diagnosis, exposure, product use, statute of limitations). | Whether a qualified claimant actually signs, and how long that takes. | Comparing vendors on intake-readiness once screening criteria are standardized. |
| CPSR | The full acquisition cost of one signed, retainer-executed case — the number that maps to docket economics. | Whether high cost came from media, screening yield, or the firm’s own closing rate. | Budgeting, vendor evaluation, and comparing acquisition cost to expected case value. |
Cost per lead (CPL)
Cost per lead is the price of one raw inquiry that clears a basic form-fill or call-in threshold. It is the cheapest and earliest number in the funnel, and the easiest for a vendor to advertise favorably. A firm evaluating two vendors purely on CPL is comparing media efficiency, not case production — two vendors can post identical CPL and produce very different signed-retainer volumes.
Cost per qualified claimant (CPQC)
Cost per qualified claimant is the price of one claimant who has cleared a defined screening script covering diagnosis, exposure, product use, or statute-of-limitations criteria. It filters out inquiries that were never going to be viable cases and shifts the screening burden — and its cost — onto the vendor, which helps firms without a large in-house intake team, provided the script itself is rigorous.
Cost per signed retainer (CPSR)
Cost per signed retainer is the full acquisition cost of one case that has actually executed a retainer agreement with the firm. It is the number that maps directly to docket economics and expected case value. It is also the metric most affected by a firm’s own intake team, so a rising CPSR does not always mean the vendor’s media or screening has gotten worse.
Pricing models in mass tort lead generation
Four pricing models dominate the market. Each moves the risk of a lead never converting to a different party — and prices accordingly.
| Pricing model | How it works | Best for | Primary risk |
|---|---|---|---|
| Cost per lead (CPL) | The firm pays a flat fee for every raw inquiry that meets basic form criteria, regardless of what happens after intake. | Firms with strong in-house intake teams that want volume and control over screening. | A cheap CPL can still produce an expensive signed retainer once answer and qualification rates are counted. |
| Cost per qualified claimant (CPQC) | The firm pays only after a claimant clears a defined screening script — diagnosis, exposure window, product use, statute of limitations. | Firms that want to shift screening labor to the vendor and pay closer to intake-ready volume. | Screening criteria can be interpreted loosely by a vendor chasing volume, so audits matter. |
| Cost per signed retainer (CPSR) | The firm pays once a claimant has executed a retainer agreement, after intake, screening, and often a case-review call. | Firms that want acquisition cost tied directly to case inventory, not funnel activity. | Highest per-unit price of the three, and it depends on the firm’s own intake team closing at a reasonable rate. |
| Flat-rate signed-case package | The firm and vendor agree on a bundled price for a set number of signed retainers within a defined tort and time window. | Firms scaling a mature, well-understood tort where volume and screening criteria are stable. | Requires a track record between firm and vendor — new relationships rarely start here. |
Vendor fee models: how the commercial arrangement is structured
The metrics above describe the unit a fee attaches to. A fee model describes the commercial arrangement itself — who carries the risk of a lead never converting. Four fee models dominate mass tort lead generation cost.
| Fee model | How the firm pays | When it fits a firm | Primary risk |
|---|---|---|---|
| Pay-per-lead (PPL) | A fixed price for every delivered lead up front, whether or not it signs. | Firms with a fast in-house intake team that want volume and full control over screening. | The firm carries all downstream risk: unsigned leads are still paid for, so a low CPL can hide an expensive CPSR, and non-exclusive leads resold to rivals erode conversion. |
| Pay-per-case / commission | The vendor is paid only when a claimant signs — a flat marketing fee per signed retainer, since a share of the legal fee is generally not permissible. | Firms that want acquisition risk shifted to the vendor and prefer to pay only for cases that reach signature. | Highest per-unit price, and percentage-of-recovery structures raise fee-splitting concerns under ABA Model Rule 5.4 — the fee must be a flat per-case amount, not a cut of attorney fees. |
| Subscription / retainer | A flat recurring fee, usually monthly, for campaign management and delivery, decoupled from volume. | Firms that want predictable budgeting and a managed program in a mature, steady-volume tort. | Cost is disconnected from output, so a slow month still bills in full; without source-level CPSR reporting the firm cannot see whether it is producing signed cases. |
| Hybrid | A reduced base fee — a subscription or discounted per-lead rate — plus a performance component tied to qualified claimants or signed retainers. | Firms that want shared risk and aligned incentives, usually once the firm and vendor have a track record together. | Added complexity: multiple fee triggers make vendors harder to compare and demand tight written definitions of what counts as qualified or signed. |
No fee model is cheapest in the abstract: the right one depends on a firm’s intake capacity, the tort’s maturity, and how much acquisition risk it wants to carry.
Budget considerations for mass tort advertising in the United States
There is no single national advertising budget for mass tort — the right number is set by how many torts a firm runs, how competitive each one is, and how many states the firm files in. Rather than a fixed dollar figure, it is more useful to think in budget bands, each defined by what it can actually prove out. The rule that holds at every band: spend below the level where a channel can generate statistically meaningful data buys noise, not cases.
Pilot / market-test tier
Enough working media to validate a new or emerging tort before committing to owned infrastructure. Data at this level is noisy and should be read as directional. The metric that matters here is qualification rate, not CPSR — you are testing whether claimant interest and eligibility justify a real build.
Single-tort scale tier
Enough sustained monthly working media in one active MDL to clear statistical-significance thresholds and drive a channel mix toward a stable cost per signed retainer. Below a meaningful monthly working-media floor per tort, channel and creative testing simply does not produce reliable data.
Multi-tort / national tier
Budget managed as a portfolio across several concurrent MDLs and multiple states or media markets. Spend is reallocated toward the torts and channels producing the lowest CPSR for the firm’s case criteria, and reporting is consolidated so a national firm sees one blended acquisition picture.
National advertising density shifts fast once a tort receives media coverage, so a budget band that cleared a stable CPSR last quarter may need to grow to hold the same position this quarter. For how the broader channel landscape sets these costs, see the mass tort advertising overview. This page covers mass tort specifically; for how mass tort budgets compare against general personal injury, see our mass tort vs. PI cost breakdown.
Why pricing differs by tort type
Mass tort lead generation cost varies by tort primarily because of three factors: how complex the eligibility criteria are, how many firms are bidding for the same audience, and how mature the tort is in the litigation lifecycle.
Case-criteria complexity
A tort with simple eligibility criteria — a single product and a short exposure window — is cheap to screen and cheap to advertise clearly. A tort with layered criteria, such as specific diagnosis codes, dosage thresholds, or multi-year exposure windows, costs more to screen and more to explain in an ad. Complex criteria also raise the disqualification rate at intake, which pushes CPQC and CPSR up even when CPL stays flat.
Competitive advertising density
When many firms bid on the same keywords and placements for a high-profile tort, auction prices rise and CPL climbs with them. A tort with only a handful of firms actively marketing it will show a materially lower CPL for the same audience size. Density can shift quickly once a tort receives national coverage, so an early CPL benchmark may not hold six months later.
Tort maturity
New torts require more audience education, which raises media cost per conversion because the ad has to do more explanatory work before a viewer responds. Mature torts benefit from familiarity and refined targeting data, which tends to lower CPL over time — though late in a tort’s life, shrinking claimant pools can push CPL back up. Browse cost ranges by active litigation →
How mass tort lead generation cost compares across torts
Applying those three drivers — criteria complexity, advertising competition, and MDL maturity — produces very different acquisition costs across torts. The comparison below is directional, ranking relative pressure on cost per signed retainer rather than quoting dollars.
| Tort | Criteria complexity | Ad competition | MDL maturity | Relative acquisition cost |
|---|---|---|---|---|
| Suboxone | Moderate | Lower | Emerging | Lower–Moderate |
| Talcum Powder | Moderate | Moderate | Mature | Moderate |
| Hair Relaxer | Moderate | Moderate | Growing | Moderate |
| Camp Lejeune | Moderate | High | Mature | Moderate–High |
| Depo-Provera | Moderate | Moderate | Emerging | Moderate–High |
| AFFF / PFAS | High | High | Growing | Higher |
| Roundup | High | High | Mature | Higher |
| Ozempic / GLP-1 | High | High | Emerging | Higher |
Ratings are illustrative and shift as torts mature and new firms enter the auction; they are not quoted prices. For indicative CPSR ranges by active litigation, see the active-campaign list.
How intake quality changes real acquisition cost
Intake quality is the single largest hidden variable in mass tort lead generation cost, because two firms buying leads at identical CPL from the same vendor can end up with very different CPSR numbers depending on how well their intake team answers, screens, and closes.
Consider a firm receiving 100 raw leads at $120 CPL, or $12,000 in media spend. If that firm’s intake team answers only 60 percent of calls promptly and converts 15 percent of those to signed retainers, it ends up with roughly 9 signed cases — a CPSR near $1,333. A second firm buying the identical 100 leads at $120 CPL, but with round-the-clock intake coverage and a structured screening script, might answer 90 percent of calls and convert 25 percent, producing about 22 signed retainers at a CPSR near $545.
Both firms bought the same leads at the same CPL. The difference came entirely from intake speed, call-coverage hours, and screening discipline, not from the quality of the media buy. This is why firms that read CPL in isolation frequently misattribute a high CPSR to bad leads when the real bottleneck sits inside their own mass tort intake process.
How law firms should evaluate lead generation ROI
Evaluating mass tort lead generation ROI means tracking a single claimant from first click through signed retainer, then comparing the resulting CPSR against the expected value of a case in that specific tort — not against a generic industry average.
Tracking from lead to retainer
Firms need a CRM configuration that tags every lead with its source campaign and follows that record through screening, case review, and signature. Without that chain intact, a firm can only report CPL and never actually calculate CPSR. Our guidance to partner firms is to require source-level tagging before any campaign scales past a test budget, so ROI can be measured honestly from day one.
When to re-evaluate a vendor on CPSR trends
A single expensive month is rarely a reason to end a vendor relationship, since CPSR moves with seasonality, ad-auction shifts, and internal intake performance. A sustained upward CPSR trend across a full quarter, isolated from known intake problems on the firm’s side, is a legitimate signal to re-evaluate. Firms weighing whether to build in-house, hire an agency, or buy from a vendor should read the agency vs. lead vendor comparison before renegotiating.
Common mistakes firms make when buying mass tort leads
Most overspending on mass tort lead generation traces back to a few avoidable mistakes. Each quietly inflates cost per signed retainer while the headline CPL still looks competitive.
- 1
Overpaying for low-quality or shared leads
Buying on the lowest headline CPL, or from a vendor reselling the same lead, means the claimant is already fielding competitor calls before intake connects. Answer and signature rates fall, and the effective CPSR climbs above an exclusive lead that cost more.
- 2
Not tracking each lead through to a signed retainer
When the CRM never tags source through screening and signature, reporting stops at CPL. The firm optimizes on raw inquiries, cannot compute CPSR, and scales whatever yields the cheapest leads, not the most signed cases.
- 3
Ignoring intake fallout
Treating the media buy as the whole cost while a slow, understaffed intake queue lets qualified claimants go cold. Good leads die before first contact, and the firm blames the media, not its own speed-to-lead.
- 4
Skipping the TCPA consent audit trail
Accepting leads with no TrustedForm or Jornaya token, disclosure language, timestamp, and IP preserved. Consent becomes unverifiable, the leads may be unusable, and the firm carries TCPA exposure it cannot document.
FAQs about mass tort lead generation cost
Straight answers to the cost questions plaintiff firms ask before committing to a lead source.
- How much do mass tort leads cost?
- Raw cost per lead (CPL) for mass tort campaigns typically ranges from roughly $50 to $300 depending on the tort, but CPL alone is a poor proxy for total cost. What a firm actually pays to acquire a signed retainer — once intake, screening, and vendor margin are included — usually runs several times higher than the headline CPL.
- What is cost per signed retainer (CPSR)?
- Cost per signed retainer is the total spend required to produce one claimant who has executed a retainer agreement with the firm. It includes media spend, agency margin, and often intake or screening fees, divided by the number of signed retainers produced — making it the most complete acquisition-cost metric available.
- Why do some torts cost more to market than others?
- Torts cost more to market when eligibility criteria are complex, when many firms bid on the same keywords and ad inventory, or when the tort is new and audiences have not been educated yet. A mature, low-competition tort with simple eligibility criteria will almost always show a lower CPL and CPSR than a crowded, complex one.
- Is CPL or CPSR the better metric for evaluating lead vendors?
- CPSR is the better metric for evaluating whether a vendor relationship is working, because it reflects the cost of an actual case rather than a raw inquiry. CPL is still useful for early-stage media efficiency comparisons, but no vendor can be judged successful or unsuccessful on CPL alone.
- What is a reasonable CPSR benchmark for mass tort campaigns?
- Reasonable CPSR benchmarks vary widely by tort, from a few thousand dollars for mature, high-volume torts to well over ten thousand dollars for complex or newly emerging litigation. The right benchmark for a given firm depends on comparing CPSR against the expected value of a signed case in that specific tort, not against a single industry-wide number.
- How do intake fees affect total lead generation cost?
- Intake fees — whether charged per call, per qualified claimant, or as a share of vendor margin — sit on top of raw media spend and directly raise the effective cost of a signed retainer. Firms that only track CPL routinely underestimate total acquisition cost because intake and screening fees are invoiced separately and never rolled into a blended number.
- Should firms ever pay for raw leads instead of qualified claimants?
- Paying for raw leads (CPL) can make sense for firms with a large, well-trained in-house intake team that wants full control over screening and is confident in its own closing rate. Firms without that intake capacity generally get better economics from a CPQC or CPSR model, even at a higher per-unit price.
- How often should a firm re-benchmark its lead generation cost?
- Firms should re-benchmark CPL, CPQC, and CPSR at least quarterly, and more often during a tort's early ramp-up when competitive density and eligibility criteria are still shifting. Pricing that looked competitive six months ago can drift out of line as more firms enter the same tort.
- What is the difference between pay-per-lead and pay-per-case pricing?
- Pay-per-lead (PPL) charges a fixed fee for each delivered lead up front, so the firm pays whether or not it signs. Pay-per-case charges only when a claimant executes a retainer, at a higher per-unit price but with conversion risk shifted to the vendor. Both are fee models layered on the CPL, CPQC, or CPSR metric they attach to.
- Can a mass tort lead vendor be paid a percentage of the case fee?
- Generally no. Paying a lead vendor a share of the attorney fee or settlement raises fee-splitting concerns under ABA Model Rule 5.4, which restricts sharing legal fees with non-lawyers. Compliant pay-per-case arrangements use a flat marketing fee per signed retainer, not a percentage of recovery. Confirm any performance-based pricing with ethics counsel and applicable state bar rules first.
Keep reading: mass tort lead generation, mass tort intake, or the 2026 ranking of mass tort marketing firms.
Ready to review your next mass tort campaign?
Tell us about your firm, target cases, and intake capacity. A strategist will respond in under 5 minutes during business hours with practical next steps.
Built for personal injury firms, intake teams, and mass tort dockets